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Daily inhaled glucocorticoids are recommended for young children at risk for asthma
exacerbations, as indicated by a positive value on the modified asthma predictive index
(API) and an exacerbation in the preceding year, but concern remains about daily adherence and effects on growth. We compared daily therapy with intermittent therapy.
Methods

We studied 278 children between the ages of 12 and 53 months who had positive
values on the modified API, recurrent wheezing episodes, and at least one exacerbation in the previous year but a low degree of impairment. Children were randomly
assigned to receive a budesonide inhalation suspension for 1 year as either an intermittent high-dose regimen (1 mg twice daily for 7 days, starting early during a
predefined respiratory tract illness) or a daily low-dose regimen (0.5 mg nightly)
with corresponding placebos. The primary outcome was the frequency of exacerbations requiring oral glucocorticoid therapy.
Results

The daily regimen of budesonide did not differ significantly from the intermittent
regimen with respect to the frequency of exacerbations, with a rate per patient-year for
the daily regimen of 0.97 (95% confidence interval [CI], 0.76 to 1.22) versus a rate of
0.95 (95% CI, 0.75 to 1.20) for the intermittent regimen (relative rate in the intermittent-regimen group, 0.99; 95% CI, 0.71 to 1.35; P = 0.60). There were also no significant
between-group differences in several other measures of asthma severity, including the
time to the first exacerbation, or adverse events. The mean exposure to budesonide
was 104 mg less with the intermittent regimen than with the daily regimen.
Conclusions

A daily low-dose regimen of budesonide was not superior to an intermittent highdose regimen in reducing asthma exacerbations. Daily administration led to greater exposure to the drug at 1 year. (Funded by the National Heart, Lung, and Blood
Institute and others; MIST ClinicalTrials.gov number, NCT00675584.)
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ecurrent wheezing episodes in preschool-age children are usually triggered by
respiratory tract infections,1,2 which often
progress to severe exacerbations requiring systemic glucocorticoids3 and frequent use of health
care services.4,5 In children under the age of 5 years
who had at least four wheezing episodes during
the previous year and positive values on the modified asthma predictive index (API) (indicating an
increased likelihood of persistent asthma in the
future),6,7 the National Asthma Education and Prevention Program Expert Panel Report 3 (EPR-3)
recommends the initiation of long-term daily inhaled glucocorticoid therapy8 on the basis of the
results of the Childhood Asthma Research and Education (CARE) Network Prevention of Early Asthma in Kids (PEAK) trial (ClinicalTrials.gov number,
NCT00272441).9 In a post hoc analysis, investigators in the PEAK trial found that daily therapy
with inhaled glucocorticoids most benefited children who had had at least one exacerbation requiring emergency or hospital care during the
previous year.10
Daily use of inhaled glucocorticoids in the
PEAK trial was associated with a small but significant reduction in height growth, as compared
with placebo, a reduction that was only partially
reversed during a 1-year observation period after
the discontinuation of study treatments.9 Concern
about growth retardation and parental resistance
to a daily regimen of inhaled glucocorticoids for
young children, who usually have only episodic
but often severe symptoms, stimulated a search
for alternative strategies — specifically, intermittent therapy with inhaled glucocorticoids. Intermittent 7-day courses of high-dose nebulized
budesonide, as compared with placebo, initiated
during respiratory tract illnesses led to significant
reductions in the severity of respiratory symptoms, without affecting linear growth, in the
CARE Network Acute Intervention Management
Strategies (AIMS) study (NCT00000622); benefits
were most apparent in children with positive values
on the modified API.11 In confirmation of these
findings, preemptive use of intermittent high-dose
fluticasone during upper respiratory illness reduced exacerbations requiring oral glucocorticoids in young children with moderate-to-severe,
virus-induced wheezing.12
We conducted the Maintenance and Intermittent Inhaled Corticosteroids in Wheezing Toddlers
(MIST) trial to determine whether a daily low-dose
regimen of budesonide would be superior to an
n engl j med 365;21

intermittent high-dose regimen in young children
who had positive values on the modified API,
along with recurrent wheezing, high-risk asthma
(≥1 exacerbation in the previous year), and low
impairment (infrequent use of albuterol and infrequent night awakenings between episodes).

Me thods
Study Patients

We enrolled children between the ages of 12 and
53 months who met all the following criteria: during the previous year, they had at least four episodes of wheezing (or three episodes of wheezing and controller use for ≥3 months), positive
values on the modified API,7 and at least one exacerbation requiring the use of systemic glucocorticoids, urgent or emergency care, or hospitalization, and during a 2-week run-in period, they
had fewer than 3 days per week of albuterol use
and fewer than 2 nights with awakening. Children
were excluded from the study if they had received
more than six courses of oral glucocorticoids or
had been hospitalized more than two times for
wheezing during the previous year. (For additional
details on inclusion and exclusion criteria, see the
Supplementary Appendix, available with the full
text of this article at NEJM.org.)
Study Design

The study, which was conducted at seven sites,
was a randomized, double-blind, parallel-group
trial. During a 2-week run-in period, all patients
received nightly placebo doses of budesonide inhalation suspension (Pulmicort Respules, AstraZeneca) and as-needed albuterol, followed by a
52-week treatment period. The full protocol and
statistical analysis plan are available at NEJM.org.
We compared the use of budesonide inhalation
suspension given in a daily low-dose regimen
with an intermittent high-dose regimen,13-18 with
matching placebos (Fig. 1A). Specific procedures
that were performed at all visits are detailed in
Figure S1 in the Supplementary Appendix. The
institutional review board at each center approved
the study. Parents or guardians (hereafter referred to as parents for simplicity, unless otherwise noted) provided written informed consent.
Intermittent high-dose treatments were started for an identified respiratory tract illness on
the basis of a published education program (see
the Supplementary Appendix).11,19 Parents began
a 7-day course of intermittent study medication
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Figure 1 (facing page). Study Design and Enrollment.
Panel A shows the study design and treatments. Intermittent high-dose nebulized budesonide inhalation suspension
was administered at a dose of 1 mg twice daily in the form of Pulmicort Respules for 7 days at the onset of a predefined
respiratory tract illness. A matched placebo was administered once nightly on all other days. Daily low-dose nebulized
budesonide inhalation suspension was administered at a dose of 0.5 mg once nightly, also in the form of Pulmicort
Respules. During respiratory tract illnesses, an appropriately matched morning placebo was used for 7 days. To maintain blinding during respiratory tract illnesses, daily treatments were discontinued for 7 days and respiratory illness
kits that were based on the study-group assignment were administered for 7 days. After 7 days, regular daily treatments were restarted. Open-label rescue albuterol was administered per protocol during a respiratory tract illness and
as needed. Study medications were administered with the use of a Pari Ultra II compressor with a Pari LC Sprint reusable nebulizer and a mask (Bubbles the Fish II or Pari Baby mask), if needed, or a mouthpiece, depending on the
age of the child. Rescue albuterol was administered at a dose of 180 μg per treatment by metered-dose inhalation
( Ventolin HFA, GlaxoSmithKline) through AeroChamber Z-STAT Plus with FlowSIGnal Whistle with ComfortSeal Mask
(Monaghan Medical) or a solution of 2.5 mg of albuterol per treatment by nebulization according to protocol during
a respiratory tract illness (four times daily, while the child was awake, for the first 48 hours) and as needed. Panel B
shows the numbers of patients who were enrolled in the study, underwent randomization, and completed the study.

at the onset of symptoms or signs of a respiratory
tract illness that they identified as their child’s
usual starting point before the development of
wheezing (Fig. S2 in the Supplementary Appendix).
These individualized symptoms or signs were re
assessed at all study visits. Parents contacted
study staff within 72 hours after starting treatment kits for respiratory tract illness, in order to
summarize the events that defined the illness.
In daily diaries, parents reported symptoms (e.g.,
nocturnal and daytime coughing, wheezing, difficulty breathing, and symptoms interfering with
activities, with the severity of each scored from
0 to 5 and with higher scores indicating greater
severity),20 medications, health care visits, and absences from day care or preschool or parental work.

Life questionnaire,21 and levels of fractional exhaled nitric oxide22 (Fig. S1 in the Supplementary
Appendix). Adherence was determined by means of
diary recordings of budesonide use. Analyses also
examined the relationship between specific nasal
respiratory viruses and respiratory tract illnesses.1
Study Oversight

The study was funded by the National Heart, Lung,
and Blood Institute and was approved by its protocol review committee and data and safety monitoring board. AstraZeneca donated budesonide
and matching placebo and reviewed the protocol
with minor comments and the manuscript without commenting; the company had no other role
in the study. The authors are fully responsible for
the study design and data (collection, analysis, comOutcome Measures
pleteness, accuracy, and interpretation), as well as
The primary outcome measure was the frequency for the fidelity of the report to the study protocol.
of exacerbations, which was defined as the number of courses of an oral glucocorticoid (predniso- Statistical Analysis
lone) started for acute wheezing after consultation The study was designed as a superiority trial of a
with a physician (by telephone or in person) on the daily low-dose regimen of budesonide, as compared
basis of a specific published protocol9,11 during with an intermittent high-dose regimen, since prethe 12-month treatment period (see the Supplemen- vious CARE trials had shown the efficacy of both
tary Appendix). About 30% of courses of an oral regimens versus placebo in similar high-risk, lowglucocorticoid were not initiated by the study team. impairment cohorts.9,11 Baseline characteristics
Secondary prespecified risk outcomes included were summarized with the use of descriptive statisthe time to exacerbations, rate of treatment fail- tics. We used the exact Wilcoxon–Mann–Whitney
ure, rate of wheezing-related health care utiliza- test, stratified according to study center and age
tion, and growth effects.7 Secondary prespecified group, to determine statistical significance.
impairment outcomes included the number of
Although the determination of statistical sigepisode-free days,11 symptom severity during a nificance for the treatment comparison was based
respiratory tract illness,11,20 absences related to on a nonparametric test, the primary research
respiratory symptoms, albuterol use, quality of question was framed in terms of the annual rate
life according to the Infant Toddler Quality of of exacerbations. For the primary parametric anal1992
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A
Run-in: 2 Weeks

Treatment Phase: 52 Weeks

Placebo once nightly and albuterol
as needed

Randomized
Treatment
Group

Nightly Except
during Respiratory
Tract Illnesses

During Respiratory
Tract Illnesses Only
for 7 Days

Daily

Budesonide (0.5 mg)

Placebo in a.m.
Budesonide (0.5 mg) in p.m.

Intermittent

Placebo

Budesonide (1.0 mg) in a.m.
Budesonide (1.0 mg) in p.m.

B
450 Children were enrolled between
August 2008 and July 2009

172 Were excluded during run-in
54 Had excessive asthma symptoms
19 Had negative asthma predictive index values
18 Were ineligible at the first visit
18 Had adherence issues
16 Had consent withdrawn
16 Had an asthma exacerbation
13 Used other asthma medications
7 Were lost to follow-up
4 Were ineligible by physician discretion
1 Had a serious adverse event
6 Had other reasons

278 Underwent randomization before end
of enrollment in July 2009

139 Were assigned to intermittentregimen group

139 Were assigned to daily-regimen
group

39 Did not complete study
26 Were lost to follow-up, or
caregivers were no longer
interested, were unable
to make visits, or withdrew consent
3 Caregivers were dissatisfied with asthma control
3 Had physician-initiated
terminations
2 Had side effects
4 Had treatment failure
1 Had another reason

26 Did not complete study
23 Were lost to follow-up, or
caregivers were no longer
interested, were unable
to make visits, or withdrew consent
1 Caregiver was dissatisfied
with asthma control
1 Had physician-initiated
termination
1 Had treatment failure

113 Completed study by August 2010

100 Completed study by August 2010

ysis, we used a negative binomial regression model
incorporating actual follow-up time so that we
could appropriately estimate the rate of exacerbation per patient-year. Secondary analyses examined the effect of treatment on other outcomes.

n engl j med 365;21

For counted outcomes, such as unscheduled health
care visits, a similar model was applied. We used
analysis of covariance for outcomes that were measured on a continuous scale, such as linear growth,
and appropriate transformations were applied for
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any outcome that had a skewed distribution. We
used a proportional-hazards regression model for
time-to-event outcomes, such as the time to the
first exacerbation. The total exposure to budeso
nide in an intention-to-treat model is described in
the Supplementary Appendix.
For sample-size determination, we used the
results of the PEAK7 and AIMS11 trials to estimate
exacerbation rates. The sample size that was required for a power of 90% was determined for a
range of exacerbation rates, from 0.6 to 1.2 per
year. On the basis of a 10% dropout rate, we calculated that a sample of 250 children would provide a power of 90% (225 total patient-years) if the
relative exacerbation rate for one treatment group
was at least 40% lower than the rate in the other
group. During the course of the trial, it became
evident that the actual noncompletion rate might
be as high as 20%. With approval from the data
and safety monitoring board and the institutional
review boards, 28 additional patients underwent
randomization, which preserved a power of 90%,
since data from 235 patient-years would be available for the intention-to-treat analysis.
All analyses were performed with the use of SAS
statistical software, version 9.1, and were adjusted
for the randomization strata. A two-sided P value
of less than 0.05 for between-group comparisons
was considered to indicate statistical significance,
with no adjustment for multiple testing of secondary outcomes.

R e sult s
Study Patients

Of the 450 children who were originally enrolled
in the study, 172 were excluded during the run-in
period. A total of 278 children underwent randomization, and 213 completed the study (Fig. 1B). The
two study groups had similar demographic and
clinical characteristics (Table 1). The noncompletion rate was 23.3%, with no significant differences
between the two groups (Tables S1 and S2 in the
Supplementary Appendix). Reported rates of adherence to treatment and diary entries were high and
similar in the two groups (Table 2). Of the reports
of treatments for respiratory tract illness, 95.6%
were made by mothers, 3.9% by fathers, 0.4% by
grandparents, and 0.1% by legal guardians.
Primary Outcome

There was no significant difference between a
daily regimen of budesonide and an intermittent
1994
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regimen with respect to the frequency of exacerbations requiring the use of rescue oral glucocorticoids, with a rate per patient-year of 0.97 (95% confidence interval [CI], 0.76 to 1.22) in the daily-regimen
group versus a rate of 0.95 (95% CI, 0.75 to 1.20)
in the intermittent-regimen group (relative rate in
the intermittent-regimen group, 0.99; 95% CI, 0.71
to 1.35; P = 0.60) (Fig. 2A and Table 2). There was
also was no significant between-group difference
with respect to the time to the first exacerbation
(hazard ratio, 0.97; 95% CI, 0.76 to 1.22; P = 0.87)
(Fig. 2B), the time to the second exacerbation (hazard ratio, 0.79; 95% CI, 0.49 to 1.32; P = 0.38), or the
frequency of treatment failure (P = 0.12).
Secondary Prespecified Outcomes

The distribution of the type of symptoms (e.g.,
coughing or wheezing) that led caregivers to recognize a respiratory tract illness and initiate treatment
was similar in the two study groups (P = 0.60) (Table S3 in the Supplementary Appendix). There were
also no significant differences in the rates of respiratory tract illness per patient-year (3.27 with
the daily regimen and 3.61 with the intermittent
regimen, P = 0.30), respiratory tract illnesses in
which prednisolone was administered (0.26 with
the daily regimen and 0.24 with the intermittent
regimen, P = 0.50) (Table 2), the frequency of treatments for respiratory tract illnesses (P = 0.30)
(Fig. 2C), and the time to the first treatment for
respiratory tract illness (P = 0.16) (Fig. 2D). Most
exacerbations occurred during treated respiratory
tract illnesses, with 102 of 111 exacerbations during treated illnesses (91.9%) in the daily-regimen
group and 105 of 115 exacerbations during treated
illnesses (91.3%) in the intermittent-regimen group.
Similarly, there were no significant between-group
differences in symptom scores during respiratory
tract illnesses (Fig. 3, and Table S4 in the Supplementary Appendix) or during exacerbations (Fig. S3
in the Supplementary Appendix).
The proportion of episode-free days across
the study was 78%, and the rate of wheezingrelated unscheduled physician visits was approximately 2.40 visits per patient-year in the two
study groups (Table 2). The rate of absences for
children and parents (from day care and work,
respectively), the proportion of days with albu
terol use (Table 2), and changes in most qualityof-life measures (Table S4 in the Supplementary
Appendix) were similar in the two study groups.
Given that measurements of fractional exhaled
nitric oxide were unsuccessful in 36% of chil-
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Table 1. Demographic and Asthma Characteristics of the Patients.*
Total
(N = 278)

Characteristic

Intermittent Regimen
(N = 139)

Daily Regimen
(N = 139)

Age of 12–32 mo — no. (%)

127 (45.7)

64 (46.0)

63 (45.3)

Male sex — no. (%)

192 (69.1)

102 (73.4)

90 (64.7)

White race — no. (%)†

173 (62.2)

91 (65.5)

82 (59.0)

Height — cm

94.2±9.1

94.0±9.1

94.5±9.0

Weight — kg

15.2±3.1

15.0±3.0

15.5±3.1

Head circumference — cm

50.0±1.9

50.1±2.0

49.9±1.9

198 (71.2)

99 (71.2)

99 (71.2)

6.7±5.4

7.0±5.9

6.4±4.7

Physician diagnosis of asthma — no. (%)
No. of wheezing episodes in past year
No. of urgent or emergency visits in past year

4.8±4.2

4.6±4.2

5.0±4.1

Hospitalizations in past year — no. (%)

53 (19.1)

26 (18.7)

27 (19.4)

114 (41.0)

55 (39.6)

59 (42.4)

Asthma controller

194 (69.8)

100 (71.9)

94 (67.6)

Inhaled glucocorticoid

189 (68.0)

96 (69.1)

93 (66.9)

Oral glucocorticoid

210 (75.5)

110 (79.1)

100 (71.9)

Tobacco-smoke exposure from birth — no. (%)
Medication use in past year — no. (%)

Allergy — no./total no. (%)
Food sensitivity
Any aeroallergen sensitivity

95/273 (34.8)

50/135 (37.0)

45/138 (32.6)

161/276 (58.3)

82/137 (59.9)

79/139 (56.8)

58

50

61

IgE — IU/ml
Median
Interquartile range
Eosinophils ≥4% — no./total no. (%)

21–186

20–195

25–179

123/260 (47.3)

61/132 (46.2)

62/128 (48.4)

146 (52.5)

76 (54.7)

70 (50.4)

Eczema — no. (%)
Allergic rhinitis — no. (%)

105 (37.8)

50 (36.0)

55 (39.6)

171/266 (64.3)

85/131 (64.9)

86/135 (63.7)

78/178 (43.8)

36/82 (43.9)

42/96 (43.8)

67±30

66±30

68±29

Coughing

0.4±0.4

0.4±0.5

0.4±0.4

Wheezing

0.1±0.3

0.2±0.3

0.1±0.3

Trouble breathing

0.1±0.3

0.1±0.3

0.1±0.2

Parental asthma — no./total no. (%)
Exhaled nitric oxide ≥10 ppb — no./total no. (%)
Episode-free days during run-in period — %
Diary scores during run-in period‡

0.1±0.2

0.1±0.2

0.1±0.3

General health perceptions from ITQOL§

Interference with activities

59.2±14.1

59.0±14.8

59.4±13.5

Any nasal virus identified — no. (%)

148 (53.2)

72 (51.8)

76 (54.7)

* Plus–minus values are means ±SD. There were no significant differences between the two groups.
† Race was determined by parents or guardians.
‡ Scores range from 0 to 5, with higher scores indicating more severe symptoms. Scores were calculated from diaries as
means ±SD for the 2-week run-in period.
§ The scores on the Infant Toddler Quality of Life (ITQOL) questionnaire range from 0 to 100, with higher scores indicating
better health.

dren at baseline, particularly in the youngest
children, changes in values for fractional exhaled nitric oxide were not reported. The frequency and distribution of respiratory viruses
in nasal secretions during two regularly scheduled clinic visits and during respiratory tract illn engl j med 365;21

nesses were similar in the two groups (Table 2,
and Table S5 in the Supplementary Appendix).
Safety

The total exposure to budesonide over the course
of the study was less in the intermittent-regimen
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Table 2. Outcomes at 1 Year.*
Intermittent Regimen
(N = 139)

Outcome

Daily Regimen
(N = 139)

Event Rate/Person-Yr (95% CI)

Treatment Effect†
Relative Rate (95% CI)

No. of prednisolone courses for asthma‡

0.95 (0.75 to 1.20)

0.97 (0.76 to 1.22)

0.99 (0.71 to 1.35)

No. of treatments for respiratory tract illness‡

3.61 (3.13 to 4.16)

3.27 (2.82 to 3.79)

1.10 (0.91 to 1.35)

No. of urgent care visits for asthma‡

2.37 (1.89 to 2.97)

2.40 (1.91 to 3.02)

0.99 (0.72 to 1.35)

No. of days absent from work, school, or day care‡

2.72 (2.00 to 3.70)

3.02 (2.22 to 4.12)

0.90 (0.59 to 1.37)

Proportion
(95% CI)

Relative Proportion
(95% CI)

Respiratory tract illnesses in which prednisolone was administered‡

0.24 (0.19 to 0.29)

0.26 (0.21 to 0.32)

Respiratory tract illnesses with virus detected in nasal sample

0.83 (0.74 to 0.92)

0.83 (0.74 to 0.93)

1.00 (0.85 to 1.17)

Respiratory tract illnesses with exacerbations and nasal virus
detected

0.79 (0.61 to 1.02)

0.78 (0.61 to 1.01)

1.00 (0.70 to 1.44)

Mean Value
(95% CI)

0.90 (0.68 to 1.19)

Mean Difference
(95% CI)

Episode-free days — %

78 (75 to 80)

78 (76 to 81)

−0.7 (−4.0 to 2.0)

Episode-free days, excluding days during treatment for respiratory
tract illness — %

85 (82 to 87)

84 (82 to 86)

0.5 (−3.0 to 4.0)

6 (5 to 7)

5 (4 to 6)

0.4 (−1.0 to 2.0)

Days with albuterol use — %
Annualized days of treatment with budesonide — no.

24 (21 to 27)

337 (330 to 344)

−314 (−322 to −306)

Cumulative dose of budesonide — mg

46 (39 to 53)

150 (140 to 160)

−104 (−116 to −92)

Value — cm

8.01 (7.71 to 8.30)

7.76 (7.45 to 8.07)

0.26 (−0.17 to 0.68)

Percentile

4.04 (2.07 to 6.00)

2.39 (0.14 to 4.64)

1.65 (−1.34 to 4.63)

z score

0.12 (0.04 to 0.20)

0.10 (0.02 to 0.18)

0.02 (−0.10 to 0.13)

Change in height from baseline

Change in weight from baseline
Value — kg

2.54 (2.37 to 2.71)

2.38 (2.20 to 2.55)

0.16 (−0.08 to 0.41)

Percentile

4.11 (2.07 to 6.16)

0.73 (−1.39 to 2.85)

3.38 (0.43 to 6.33)

z score

0.15 (0.07 to 0.22)

0.05 (−0.03 to 0.13)

0.10 (−0.01 to 0.21)

Change in head circumference from baseline
0.92 (0.79 to 1.05)

0.87 (0.74 to 1.00)

0.05 (−0.14 to 0.23)

Percentile

Value — cm

−1.20 (−3.45 to 1.04)

−3.59 (−6.67 to −0.51)

2.39 (−1.43 to 6.20)

z score

−0.07 (−0.17 to 0.03)

−0.13 (−0.24 to −0.02)

0.06 (−0.09 to 0.21)

Days with diary-card adherence — %

83 (78 to 88)

88 (84 to 92)

−5 (−11 to 2)

Daily

94 (93 to 96)

95 (94 to 96)

−1 (−2 to 1)

During respiratory tract illness

81 (75 to 87)

82 (75 to 89)

−1 (−10 to 8)

Days with adherence to budesonide or placebo — %§

* All outcomes have been adjusted for age and clinical center. Growth was measured in 113 children in the intermittent-regimen group and
110 in the daily-regimen group. All other outcomes included data from the entire cohort.
† The treatment effect was calculated as the value in the intermittent-regimen group divided by the value in the daily-regimen group.
‡ Models were also adjusted for sex, race, and atopy, since results were similar with adjustment for age and clinical center only.
§ Treatment adherence was evaluated on days for which diary data were available.

group (45.7 mg; 95% CI, 38.9 to 52.8) than in the
daily-regimen group (149.9 mg; 95% CI, 140.1
to 159.6), with an average reduction of 104 mg
(95% CI, -116 to -92) in the intermittent-regimen
1996
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group. Between-group differences in changes in
height, weight, and head circumference were not
significant (Table 2, and Fig. S4 in the Supplementary Appendix).

nejm.org

november 24, 2011

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on May 27, 2014. For personal use only. No other uses without permission.
Copyright © 2011 Massachusetts Medical Society. All rights reserved.

Daily or Intermittent Budesonide for Wheezing

A Frequency of Exacerbations
70

100

Patients without a Course
of Prednisolone (%)

60

Patients (%)

B Time to First Exacerbation
Daily regimen

Intermittent regimen
P=0.60

50
40
30
20
10
0

1

2

3

4

5

Intermittent
regimen

60
40
20
0

0

Daily regimen

80

P=0.87
0

No. of Prednisolone Courses

20
15
10
5
0

0

1

2

3

4

5

6

7

200

250

300

350

71
66

64
54

50
40

400

8

114
114

100
93

89
84

78
74

D Time to First Treatment for Respiratory Tract Illness

Daily regimen

Patients without Treatment for
Respiratory Tract Illness (%)

Patients (%)

25

150

No. at Risk

C Frequency of Treatments for Respiratory Tract Illness
Intermittent regimen
P=0.30

100

Days
Intermittent regimen 139
Daily regimen
139

30

50

6

9

100
80
60
Daily regimen

40
20
0

P=0.16
0

50

Intermittent regimen
100

150

10

No. of Treatments for Respiratory Tract Illness

200

250

300

350

19
23

17
20

15
16

400

Days
No. at Risk
Intermittent regimen 139
Daily regimen
139

61
78

39
46

29
39

24
30

Figure 2. Exacerbations of Wheezing and Respiratory Tract Illness.
P values are based on exact Wilcoxon–Mann–Whitney tests for Panels A and C and on Wald tests from a proportional-hazards regression
model for Panels B and D. All comparisons have been adjusted for clinical center and age.

for 7 days during a predefined respiratory tract
illness, with respect to the frequency of exacerbations (the primary outcome) in preschool-age children at risk for asthma and future exacerbations.
In addition, there was no significant betweengroup difference in respiratory symptoms (symptom severity during respiratory tract illnesses,
episode-free days, and bronchodilator use) or quality of life. These findings occurred in the context
of similar rates of reported adherence and identification of nasal viruses in the two study groups.
The treatment of preschool-age children with
recurrent wheezing is complex, since most of these
children do not have persistent asthma, as defined
by regular symptoms, and the diagnosis is diffiDiscussion
cult to confirm. U.S. guidelines8 recognize this
We report that a daily low-dose regimen of budes complexity in regard to diagnosis and management
onide inhalation suspension was not superior to and recommend daily therapy with inhaled gluco
an intermittent high-dose regimen, administered corticoids as the preferred option for young chilThere were no deaths. The proportions of patients with serious adverse events (including all
hospitalizations) and nonserious adverse events
did not differ significantly in the two study groups
(Table S6 in the Supplementary Appendix). Four
children in the daily-regimen group and five in
the intermittent-regimen group were hospitalized
for asthma exacerbations. Other reasons for hospitalization were pneumonia, gastroenteritis, and
diarrhea (one patient each) in the daily-regimen
group and concussion, gastroenteritis, influenza,
tonsillectomy, and motor-vehicle accident (one patient each) in the intermittent-regimen group.
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Intermittent regimen
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Daily regimen

B Wheezing
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D Trouble Breathing
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Figure 3. Profiles of Symptom Severity during Respiratory Tract Illness.
Day zero corresponds to the start of treatment for a respiratory tract illness. P values are for comparisons of symptom levels during the first 14 days after the initiation of treatment for respiratory tract illness, with adjustment for
baseline symptom levels (on days 13 to 7 before the initiation of treatment). Plotted values are means for the indicated day. Scores range from 0 to 5, with higher scores indicating more severe symptoms.

dren with recurrent wheezing and risk factors
for persistent asthma (i.e., positive values on the
modified API),8 although this treatment does not
alter the course of the disease after the inhaled
glucocorticoids are discontinued.9 Guidelines of
the Global Initiative for Asthma (GINA)23 also recommend daily controller therapy, including the use
of inhaled glucocorticoids, for young children with
intermittent wheezing, a history suggestive of
asthma, and at least three wheezing episodes in
the previous year. The guidelines caution against
the use of daily high-dose therapy with inhaled
glucocorticoids for prolonged periods, given the
reported effect of such use on growth, and advise
using the lowest dose necessary for asthma control.8 In this context, the inability to show the superiority of a daily low-dose regimen of budesonide
over an intermittent high-dose regimen may be
important in the preparation of future guidelines.

1998

n engl j med 365;21

The efficacy of daily low-dose inhaled glucocorticoids, as compared with placebo, has been documented in studies ranging from 1.5 to 12 months
and involving preschool-age children with positive
values on the modified API,9 risk factors for asthma,24-26 frequent recurrent wheezing or asthma
symptoms,27,28 or physician-diagnosed asthma.13,29
A recent meta-analysis30 and both the EPR-3
national guidelines8 and GINA guidelines23 for
infants and preschool-age children support these
findings. In the PEAK trial, the daily low-dose inhaled glucocorticoid that was shown to be efficacious was fluticasone administered in a metereddose inhaler, but there has been no evidence that
efficacy differs when other inhaled glucocorticoids
are used in clinically similar doses.8,10 In preschoolage children who entered a trial with frequent
symptoms, the percentage of symptom-free days
was higher among those receiving daily inhaled
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glucocorticoids than among those receiving placebo, but the comparison between daily use and
as-needed use was not significant.31 On the other
hand, the use of intermittent high-dose inhaled
glucocorticoids for specified periods was more
effective than placebo in preschool-age children
with intermittent, recurrent wheezing12,32,33 and
in those at high risk for asthma but with low
levels of respiratory impairment.11 Thus, we determined that a placebo group was not indicated
for our study, which involved children who had
low impairment but were at high risk for emerging,
persistent asthma and recurrence of an asthma
exacerbation, a decision that was approved by the
independent oversight boards.
Budesonide inhalation suspension was selected
for the daily low-dose inhaled glucocorticoid since
it was the only such drug approved by the Food
and Drug Administration for daily use in children
between the ages of 1 and 4 years at recommended
starting daily doses of 0.5 to 1.0 mg on the basis
of pivotal trials of budesonide versus placebo in
children between the ages of 1 and 8 years.13-15
In post hoc analyses, daily doses of 0.5 and 1.0 mg
of budesonide were similarly effective in children
under the age of 4 years and in those 4 years of age
or older.34 Budesonide in a daily dose of 0.5 mg
was also associated with fewer exacerbations and
less impairment than was cromolyn17 or monte
lukast16 in young children. The efficacy of oncedaily budesonide by nebulization (including a dose
of 0.5 mg) has been summarized previously.35 In
addition, guidelines recommend a daily dose of
0.5 mg of budesonide as a low-dose inhaled gluco
corticoid.8,23 As compared with placebo, budes
onide was efficacious without retarding growth
when used in an intermittent high-dose regimen
of 1 mg twice daily for 7 days with each respiratory tract illness in preschool-age children.11
Our findings may not be applicable to young
children whose asthma was different from or
more severe than that of the children in our
study. Daily36 or intermittent 31,37 use of inhaled
glucocorticoids or even short courses of oral glucocorticoids started at the onset of wheezing episodes38,39 may not be efficacious in preschool-age
children with a first episode, with transient or infrequent wheezing, or without an asthma diagnosis
or a high risk of asthma.
Although the observed exacerbation rates in
the two study groups were numerically similar,

n engl j med 365;21

our results do not show with certainty that the
two treatments were equally effective. The uncertainty is reflected in the confidence interval
for the relative rate of exacerbations, which extends from approximately 0.7 to 1.35, so our data
do not rule out the possibility that either treatment could be up to 35% more effective than the
other. The advantage of the intermittent regimen
over the daily regimen cannot be based on differential effects on growth, but rather on a reduced
exposure to inhaled glucocorticoids (approximately 100 mg less during the course of a year, or a
reduction in exposure by a factor of 3.3). The noncompletion rate was higher than anticipated but
similar in the two groups, as were the characteristics of the children who did not complete
the study.
A major advantage of an intermittent regimen
of inhaled glucocorticoids is that its initiation
occurs early during a predefined respiratory tract
illness on the basis of individualized symptoms
that historically have occurred before the onset
of wheezing.11 This strategy avoids the use of inhaled glucocorticoids for each upper respiratory
tract illness and thus allows for the benefits of the
regimen at considerably lower cumulative levels of
exposure. In our study, intermittent budesonide
was initiated on average once every 3.5 months, in
contrast to a monthly rate when such therapy was
started preemptively with each upper respiratory
tract infection.12 This finding may explain the
adverse effects on growth in the latter study,12
as compared with our approach.11 Nevertheless,
parents require careful, individualized instruction
on when to start budesonide in order to ensure
that this intermittent approach is used appropriately, as detailed previously11,19 (Fig. S2 in the Supplementary Appendix).
In summary, our trial compared the efficacy
of an early intermittent high-dose regimen of bu
desonide for respiratory tract illness with that of
a daily low-dose regimen, with the latter recommended by current guidelines for preschool-age
children with recurrent wheezing episodes and
positive values on the modified API. We conclude
that for such children who have had one or more
exacerbations requiring the use of systemic glucocorticoids, urgent or emergency medical visits,
or hospitalizations during the previous year but
a documented history of low impairment from
asthma, the daily low-dose regimen of budes
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onide was not superior to an intermittent highdose regimen initiated during a predefined res
piratory tract illness in reducing exacerbations.
Moreover, the daily low-dose regimen was associated with more frequent administration of
and greater exposure to budesonide.
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